Science News
from research organizations

New Multiple Myeloma Treatment Induced Total Remission In 33 Percent Of Patients

June 5, 2007
Institut d'Investigacions Biomèdiques August Pi i Sunyer
A new study shows that the alternating treatment of two drugs before autologous bone marrow transplantation improves the post-transplantation response. The largest anti-myeloma effect of drugs was assessed in the earliest periods of medication, and this fact sets the basis for new research lines on the reduction of the total number of treatment cycles in order to allow an earlier transplantation. This would result in costs and medication reduction.

A study, lead by Dr. Laura Rosiñol, researcher of the Haematooncology Group of Hospital Clínic-IDIBAPS (Barcelona) in collaboration with Dr Joan Blade, researcher in the same group, administered alternately two drugs (Bortezomid and Dexamethasone) before conducting autologous bone marrow transplantations. The aim of this second phase trial was to assess the treatment's overall response rate, its toxicity in patients, the possibility of recovery of innate stem cells, and the response kinetics which is calculated by measuring M-protein concentrations in serum and urine. M-protein is associated with myeloma presence.

This research work, conducted in the frame of the PETHEMA network, has been coordinated by Hospital Clínic de Barcelona and had the participation of eight more Spanish hospitals: Hospital Germans Trias i Pujol, Hospital Clínico Salamanca, Hospital de Sant Pau, Hospital Clínico de Madrid, Hospital La Princesa, Hospital 12 de Octubre and Hospital La Fe. A total of 40 patients between 41 and 65 years with newly diagnosed multiple myeloma participated in this study. All of them underwent six treatment cycles with a 10-day break between each, and were administered Bortezomid or Dexamethasone alternately.

This study has showed very relevant facts. The first notable fact is that there was a global reduction of M-protein concentration in both urine and plasma, reflecting a global reduction of tumour cells. Thus, a highly efficient anti-myeloma effect was observed, and the post autologous transplantation response index was favourable: a 94% response, one third of which (33%) was of complete response (CR) and 22% was a very good partial response (VGPR).

Another surprising result was the speed at which the effect was achieved -- i.e. the highest reduction in M-protein was detected within the first four treatment cycles. It should be mentioned that the first two cycles already caused an 82% reduction. These results set the base for further clinical trials in order to reduce the total number of previous medication cycles. A change like this in the therapeutic guidelines would not only anticipate transplantation but would also result in reduction of both economical costs and medication.

Last but not least, the observed good treatment tolerance and the ample recovery of bone marrow stem cells reinforce this therapy as the best option against multiple myeloma before autologous transplantation.

About multiple myeloma

Multiple myeloma is a type of bone marrow cancer, consisting in abnormal proliferation of plasma cells --blood cells producing antibodies that help the body's immune system fight disease. The treatment for this kind of cancer consists of a therapy provoking a decrease in tumour cells previous to successful autologous bone marrow stem cells transplantation.

The pre-transplantation therapy used until now made patients undergo chemotherapy. This treatment form did not assure the posterior recovery of the patients' own stem cells, while causing significantly increased toxicity levels. For this reason, a number of studies alternating drugs have been conducted during the last years, being less toxic for the patient, highly aggressive against myeloma and allowing optimal recovery of stem cells.

An example is the study that used Thalidomide and Bortezomid. In the first place the US FDA approved the use of Thalidomide combined with Dexamethasone (Rajkumar SV et al ) but the treatment only gave a slightly elevated total remission and no overall improvement was observed after transplantation. In a second case, Bortezomid was administered together with Dexamethasone (Jagannath et al ). The total remission results were notable, but toxicity levels in patients was still too high.

Story Source:

The above post is reprinted from materials provided by Institut d'Investigacions Biomèdiques August Pi i Sunyer. Note: Materials may be edited for content and length.

Cite This Page:

Institut d'Investigacions Biomèdiques August Pi i Sunyer. "New Multiple Myeloma Treatment Induced Total Remission In 33 Percent Of Patients." ScienceDaily. ScienceDaily, 5 June 2007. <>.
Institut d'Investigacions Biomèdiques August Pi i Sunyer. (2007, June 5). New Multiple Myeloma Treatment Induced Total Remission In 33 Percent Of Patients. ScienceDaily. Retrieved July 4, 2015 from
Institut d'Investigacions Biomèdiques August Pi i Sunyer. "New Multiple Myeloma Treatment Induced Total Remission In 33 Percent Of Patients." ScienceDaily. (accessed July 4, 2015).

Share This Page: